Small-Molecule Therapeutic
Prostate Cancer
Key Facts
About AIkido Labs
AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.
View full company profileAbout AIkido Labs
AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.
View full company profileAbout AIkido Labs
AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.
View full company profileAbout AIkido Labs
AIkido Labs Inc. (NASDAQ: AIKI) is a pre-revenue, pre-clinical biotech developer focused on aggregating and advancing early-stage therapeutic assets from top-tier universities. Its core strategy involves securing exclusive worldwide licenses to build a pipeline targeting prostate cancer, pancreatic cancer, AML, ALL, and a pan-viral antiviral platform. The company's primary achievements include establishing key partnerships with institutions like the University of Maryland, Baltimore, The University of Texas, and Wake Forest University, and positioning itself in the public markets to fund its asset development through strategic capital raises.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| Leronlimab | CytoDyn | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |
| Mitomic™ Test for Prostate Cancer | MDNA Life Sciences | Development/Validation |
| Immunomodulator Platform | OmniCyte | Research |
| Prostate cancer 'super test' | EDX Medical | Development |
| PSMA-Dex | DexTech Medical | Pre-clinical |
| Prostate Cancer Development Program | Delta4 AI | Preclinical |